Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in spain : A retrospective cohort study by Román, Marta et al.
Trends in Detection of Invasive Cancer and Ductal
Carcinoma In Situ at Biennial Screening Mammography
in Spain: A Retrospective Cohort Study
Marta Roma´n1,2, Montse Rue´2,3, Maria Sala1,2,4, Nieves Ascunce5, Marisa Bare´6, Araceli Baroja7,
Mariola De la Vega8, Jaume Galcera´n9, Carmen Natal10, Dolores Salas11, Mercedes Sa´nchez-Jacob12,
Raquel Zubizarreta13, Xavier Castells1,2,4*, the Cumulative False Positive Risk Group"
1Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain, 2Network for Research into Healthcare in Chronic
Diseases (REDISECC), Madrid, Spain, 3 Basic Medical Sciences Department, Biomedical Research Institut of Lleida (IRBLLEIDA)-University of Lleida, Lleida, Spain,
4Universitat Auto`noma de Barcelona, Barcelona, Spain, 5Navarra Breast Cancer Screening Programme, Public Health Institute, Pamplona, Navarra, Spain, 6Oficina
Te`cnica de Cribratge, Corporacio´ Sanitaria Parc Taulı´-Institut Universitari Parc Taulı´-UAB, Sabadell, Barcelona, Spain, 7 La Rioja Breast Cancer Screening Programme,
Fundacion Rioja Salud, Logron˜o, La Rioja, Spain, 8Direccio´n General de Programas Asistenciales, Consejerı´a de Sanidad, Servicio Canario de Salud, Tenerife, Santa Cruz de
Tenerife, Spain, 9 Foundation Society for Cancer Research and Prevention, Pere Virgili Health Research Institute, Reus, Tarragona, Spain, 10 Program & Analysis Unit, Health
Office, Oviedo, Principado de Asturias, Spain, 11General Directorate Public Health & Centre for Public Health Research, Valencia, Comunidad Valenciana, Spain, 12 Servicio
de Promocio´n de la Salud y Programas Preventivos, Consejerı´a de Sanidad, Valladolid, Castilla y Leo´n, Spain, 13Galician Breast Cancer Screening Programme, Public
Health & Planning Directorate, Health Office, Santiago de Compostela, La Corun˜a, Spain
Abstract
Background: Breast cancer incidence has decreased in the last decade, while the incidence of ductal carcinoma in situ
(DCIS) has increased substantially in the western world. The phenomenon has been attributed to the widespread adaption
of screening mammography. The aim of the study was to evaluate the temporal trends in the rates of screen detected
invasive cancers and DCIS, and to compare the observed trends with respect to hormone replacement therapy (HRT) use
along the same study period.
Methods: Retrospective cohort study of 1,564,080 women aged 45–69 years who underwent 4,705,681 screening
mammograms from 1992 to 2006. Age-adjusted rates of screen detected invasive cancer, DCIS, and HRT use were calculated
for first and subsequent screenings. Poisson regression was used to evaluate the existence of a change-point in trend, and
to estimate the adjusted trends in screen detected invasive breast cancer and DCIS over the study period.
Results: The rates of screen detected invasive cancer per 100.000 screened women were 394.0 at first screening, and 229.9
at subsequent screen. The rates of screen detected DCIS per 100.000 screened women were 66.8 at first screen and 43.9 at
subsequent screens. No evidence of a change point in trend in the rates of DCIS and invasive cancers over the study period
were found. Screen detected DCIS increased at a steady 2.5% per year (95% CI: 1.3; 3.8), while invasive cancers were stable.
Conclusion: Despite the observed decrease in breast cancer incidence in the population, the rates of screen detected
invasive cancer remained stable during the study period. The proportion of DCIS among screen detected breast
malignancies increased from 13% to 17% throughout the study period. The rates of screen detected invasive cancer and
DCIS were independent of the decreasing trend in HRT use observed among screened women after 2002.
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Introduction
Breast cancer is the most frequent tumour in women worldwide,
and its incidence rates had risen steadily worldwide over these past
decades [1]. However, since the early 2000’s a downturn in its
incidence rates have been reported in several developed countries
[2–10]. The downturn has also been observed in Spain, more
remarkably in women on the 45–69 age range [11,12]. The
phenomenon has been attributed to the widespread adaption of
screening mammography once screening saturation was nearly
achieved [11–13], as well as to the reduction in the use of hormone
replacement therapy (HRT) among post menopausal women after
the publication of the results of the Women’s Health Initiative trial
in 2002 [14]. The prevalence of HRT use in Spain has always
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been low compared to other countries [11,15–17]. Furthermore,
the decline in breast cancer incidence due to the reduction in
HRT use has not been studied in Spain.
Different trends have been observed in the incidence of invasive
cancer compared to ductal carcinoma in situ (DCIS). While the
incidence of invasive cancer has declined in the last decade, the
incidence of DCIS of the breast has increased in several countries
[18–22]. DCIS have substantially increased in the proportion of
breast malignancies detected. The increase has been attributed to
the implementation of breast cancer screening [21,23]. It is
estimated that DCIS represents 20% of screen detected breast
malignancies [21,24].
The availability of individual level data from a cohort of
screened women in Spain, followed during 15 years provides the
opportunity to analyze the screen detected rates of invasive breast
cancer and DCIS over time. We wanted to evaluate the temporal
trends in the rates of screen detected invasive cancers and DCIS,
and to study the temporal trends with respect to the HRT use
along the same study period.
Methods
Ethics Statement
The study was approved by the Mar Teaching Hospital
Research Ethics Committee. The data was analyzed anonymously
and therefore no additional informed consent was required.
Setting
The National Health System in Spain provides universal health
coverage, including early detection of breast carcinoma. All
women residing in Spain aged 50 to 69 years are actively invited to
participate in population-based screening, with screening intervals
every 2 years. However, some regions start inviting women at 45
years. Population-based breast cancer screening in Spain started in
one region in 1990 and was implemented nationwide in 2005.
Breast cancer screening in Spain follows the European Guidelines
for Quality Assurance in Mammographic Screening [25] and its
results meet the required standards [26]. Data from eight regions
of Spain that perform population-based breast cancer screening
were collected. The participating regions covered 44% of the
Spanish target population for breast cancer screening in 2006. The
participating women are provided with a unique personal
identification number. Information about attendance, screening
outcome, and diagnostic work-up was registered at an individual
level in each screening region data base with the unique personal
identification number.
Study Population and Data Collection
Information was collected from 1,564,080 women aged 45 to 69
years of age who had undergone at least one biennial screening
examination between 1992 and December 2006. The women
underwent 4,705,681 screening examinations during the study
period. Due to the small sample size, information on screening
examinations performed in 1990 and 1991 was not used for the
study.
At the time of each screening examination information is
routinely collected related to the mammographic interpretation,
whether or not the woman was recalled for additional evaluation
to rule out or confirm malignancy, and the specific additional
evaluations performed, if any. Additional evaluation for breast
cancer assessment included additional mammography, magnetic
resonance imaging, ultrasonography, fine-needle aspiration cytol-
ogy, core-needle biopsy and open surgical biopsy. The diagnostic
work-up for additional evaluation was carried out within a
maximum of 2 months after screening. A definitive diagnosis of
breast cancer was always histopathologically confirmed. Informa-
tion on histopathology classification was routinely collected in the
screening regions for screen detected cancers using the ICD-10
classification codes. A case was considered as screen detected if the
diagnosis was made on the basis of a screening examination with
subsequent diagnosis work-up procedures. Cases were classified as
DCIS or invasive breast cancer.
In addition, information on HRT use was obtained through a
questionnaire administered face-to face by a trained health
professional at each screening visit immediately before the
screening examination. Women were considered to be users of
hormone replacement therapy at a screening examination if they
reported to be current users or to have used hormone therapy in
the sixth months previous to that visit.
Statistical Analysis
Age-adjusted rates of screen detected invasive cancer and DCIS
were calculated for first and subsequent screenings and 3-year
period (1992–1994, 1995–1997, 1998–2000, 2001–2003, 2004–
2006). The Age-adjusted rates of invasive breast cancer, DCIS,
and HRT use among the screened women, were calculated for
each calendar year. Age-specific incidence rates of invasive cancer
and DCIS by 5 year age groups were computed standardized by
first or subsequent screen. All age-standardizations were done
using the direct method and the European standard population in
5-year age groups as reference.
Poisson regression analyses were used to estimate the trends in
screen detected rates of invasive breast cancer and DCIS observed
in the study population over the 15 year period. Calendar year,
screening region, 5-year age groups and first/subsequent screen
were used as explanatory variables. The estimated annual
percentage change (APC) and 95% confidence intervals were
obtained from the regression models. The APC was equal to 100
(em -1), where m is the coefficient of the variable of calendar year.
Independent models were computed to evaluate the breast cancer
trends of DCIS and invasive cancer separately, and to ascertain
possible differences in the APC for first and subsequent screens.
In addition, changes in age- and region-adjusted detection rates
of DCIS and invasive cancer over the study period were evaluated
using transition change-point models [11,27]. These models
assume a Poisson distribution for the number of cases in each
stratum and afford a statistical test for the existence of a change-
point in the overall trend, and where this is the case, estimate the
year in which the change-point is located and the APC before and
after the change point. Overall significance level was set at P-
value,0.05. Statistical analyses were performed using SAS 9.1
(SAS Institute, Cary, NC, USA) and R (R Foundation for
Statistical Computing, Vienna, Austria).
Results
Twenty nine percent of women were first screened at 45 to 49
years of age, and 30% at age 50 to 54 years (table 1). The crude
number of screen detected cancers per 1,000 screening examina-
tions increased with age, with and overall crude number of 2.73
per 1,000 screening examinations (table 1).
A total of 16,309 screen detected cancers were diagnosed in the
1992–2006 period analyzed. Of these cancers 78.8% (n = 12,851)
were invasive cancers, 14.6% (n = 2,379) were DCIS, and 6.6%
(n = 1,079) were unknown. At first screen 6,845 cancers were
detected (14.6% DCIS, 76.7% invasive and 8.8% unknown) and
9,464 at subsequent screens (14.6% DCIS, 80.3% invasive and
5.1% unknown). Mean (standard deviation) age at detection of
Cancer Detection Trends at Mammographic Screening
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DCIS was 56.7 (6.39) and for invasive cancers was 57.8 (6.23) (P
value,0.001).
Overall age-adjusted screen detected cancer rates were higher at
first screening compared with subsequent screens for both, DCIS
and invasive cancer (table 2). The screen detected rates of DCIS
increased by 3-year period for first and subsequent screens. The
highest screen detected rate of invasive cancer was observed in the
1998–2000 period for first screen, and in the 1992–1994 period for
subsequent screens (table 2).
The overall age-specific rates of invasive cancer per 100,000
women-years increased with age. It was 215.8 for women aged 45–
49 years, 232 at 50–54 years, 258 at 55–59 years, 332 at 60–64
years, and 380 at 65–69 years. The overall age-specific rates of
DCIS per 100,000 women-years was 55 for women aged 45–49
years, 47 at 50–54 years, 48 at 55–59 years, 51 at 60–64 years, and
59 at 65–69 years.
After adjustment for age, screening region, and first or
subsequent screen, the Poisson regression showed an absence of
trend over the period studied for invasive cancers (p-value = 0.29),
with a non-significant increase of 0.3% per year (APC 0.3, 95%
CI: 20.2; 0.8), and a statistically significant increase of DCIS of
2.5% per year (APC 2.5, 95% CI: 1.3; 3.8). Figures 1a and 1b
show the overall trends for first and subsequent screens for both,
DCIS and invasive cancers. Fig. 1a shows that the incidence of
screen detected invasive cancer was stable for first and subsequent
screens with no significant trends over the period studied (p-
value = 0.12 and 0.15 respectively for first and subsequent screens).
As Fig. 1b depicts, the incidence of screen detected DCIS steadily
increased along the study period for both, first and subsequent
screens. The detection rates for DCIS increased by 2.9% per year
for the first screen and 2.6% for the subsequent screens. There was
no evidence of a change point in trend in the rates of DCIS and
invasive cancers over the 17 year period studied (p-value for the
existence of a change point = 0.3 for invasive cancer and p-
value = 0.7 for DCIS).
Table 3 shows time trends for the rates of screen detected DCIS
and invasive cancer by 5-year age groups over the study period.
The P values refer to the evaluation of the existence of a change-
point in the overall trend. Estimates for the APC and 95% CI were
obtained from the Poisson regression model for each 5-year age
group, adjusted for screening region and first or subsequent screen.
There was no evidence of a change point in trend among any of
the 5-year age groups, for neither invasive cancers nor DCIS. No
significant APC was found for any 5-year age group over the study
period for screen detected invasive cancers. The APC of screen
detected DCIS showed a significant increase over the study period
for the 45–49, 50–54, and 55–59 years age groups (table 3).
We presented data on HRT use by the screened women in our
data set, obtained from the administered questionnaire at the time
of screening examination. Information on HRT use was available
in 69.3% of screening examinations. The percentage of missing
information on HRT use was stable in the study period. An
Table 1. Number of women screened, screening examinations, screen detected ductal carcinoma in situ (DCIS) and invasive breast
cancers by 5-year age groups.
Women screeneda Screening examinationsb Screen detected DCISc Screen detected invasive cancerc
Age n n n (%) n (%)
45–49 464,434 764,069 421 (0.55) 1649 (2.16)
50–54 477,084 1,219,228 571 (0.47) 2831 (2.32)
55–59 300,245 1,191,627 572 (0.48) 3076 (2.58)
60–64 260,264 1,084,986 554 (0.51) 3600 (3.32)
65–69 62,053 445,771 261 (0.59) 1695 (3.80)
Overall 1,564,080 4,705,681 2379 (0.51) 12,851 (2.73)
aNumber of women with that given age at first screening examination.
bNumber of screening examinations performed in women at that given age.
c% calculated as number of cases per 1000 screening examinations.
doi:10.1371/journal.pone.0083121.t001
Table 2. Age-adjusted incidence rates of screen detected ductal carcinoma in situ (DCIS) and invasive breast cancer (per 100,000
European standard population) by period and first or subsequent screen.
First screen Subsequent screen
DCIS Invasive breast cancer DCIS Invasive breast cancer
Period (3-years) No. of cases Rate No. of cases Rate No. of cases Rate No. of cases Rate
1992–1994 116 60.5 681 357.8 24 39.7 162 266.4
1995–1997 185 65.4 1,037 378.8 127 43.7 666 221.2
1998–2000 257 64.7 1,544 426.1 236 40.7 1,365 222.9
2001–2003 235 69.9 1,140 409.0 414 43.6 2,377 236.6
2004–2006 203 70.3 846 372.3 582 45.8 3,033 228.7
Overall 996 66.8 5,248 394.0 1,383 43.9 7,603 229.9
doi:10.1371/journal.pone.0083121.t002
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increase in the prevalence of HRT use was observed from 1992 up
to 2003. HRT use from 1992 to 1996 was relatively low with a
prevalence of 2,749 HRT users per 100,000 women-years in 1996
(fig. 2). A large increase in HRT use was observed from 1997 to
2003 when the prevalence level peaked (13,303 per 100,000
women-years). A decrease was observed after 2003, with a
prevalence of HRT users of 9,344 per 100,000 women-years in
2006. A stable incidence of screen detected invasive cancer in the
study period is shown in figure 2, independently of the HRT use
among screened women. Similarly, the steady increase of 2.5% per
year in the incidence of screen detected DCIS showed to be
independent of the HRT use among the screened women.
Discussion
Our results showed a steady increase of screen detected DCIS in
Spain in the 1992–2006 period studied. The steady increase was
observed for first and subsequent screens, and it was more
markedly observed in screened women in the younger age groups.
Despite the observed downturn in the population incidence of
invasive cancer in women on the 45–69 age range the incidence of
screen detected invasive cancers showed an absence of trend in the
study period. The observed rates of screen detected DCIS and
invasive cancer showed to be independent of HRT use among
screened women.
The absence of trend in screen detected invasive cancers is in
accordance with a previous study by Nederend et al. that reported
an absence of trend in the rates of screen detected advanced
cancers during a 12 year period [28]. With respect to DCIS,
previous studies have shown an increase in the detection rates of
DCIS. Van Steenbergen et al. found a ten-fold increase in the
detection rate of DCIS between 1991 and 2000 in southern
Netherlands, and a two-fold increase was found by Barchielli et al.
in Italy [18,22]. The widespread adaption of screening mammog-
raphy has often been used to explain the increase in the incidence
of DCIS in the general population found in several studies
[18,21,22,29,30]. However, our study is targeted exclusively to
screening participants and our findings should be interpreted in
the screening setting. A reason for the increase in screen detected
DCIS could be the changes in the techniques and interpretation of
screening mammograms over time, as well as the changes in the
pathological classification of pre-malignant breast lesions. Popu-
lation-based screening in Europe follows the recommendations of
the European guidelines [25], but programs have progressively
improved their quality indicators and efficiency over the years. On
the other hand, the introduction of digital mammography has
increased the sensitivity of screening mammography, more
markedly in the detection of DCIS [31–34]. However, less than
1.5% of screening test were performed with digital mammography
in this study.
The steady increase in screen detected DCIS over the study
period while the screen detected invasive cancers remained stable
has caused that DCIS have substantially increased in the
proportion of breast malignancies detected in screening mam-
mography. The proportion has increased from 13% in 1994 to
17% in 2006. The observed proportion of screen detected DCIS
among all malignancies observed in the last part of the period
(17%) was similar to what has been reported (18%) in other
European countries [21].
The rates of screen detected invasive cancer by 5-years age
groups showed no trend after adjustment for screening region and
first or subsequent screen. The absence of trend in the 5-years age
groups reinforced the idea of a steady, stable detection rate of
invasive cancers along the study period. On the other hand, the
rates of DCIS by 5-years age groups showed a statistically
significant increase for the 45–49, 50–54, and 55–59 years age
groups. The estimated increase in the rates of DCIS in the three
youngest age groups showed a decreasing gradient with age that
Table 3. Trends in rates of screen detected ductal carcinoma in situ (DCIS) and invasive breast cancer in the 1992–2006 period by
5-year age groups.
DCIS Invasive breast cancer
Change-point
p-valuea Annual percentage change
b
Change-point
p-valuea Annual percentage change
b
Age Overall 95% CI Overall 95% CI
45–49 0.48 3.9 1.2; 6.5c 0.22 0.5 20.8; 1.8
50–54 1.00 3.0 0.4; 5.6c 0.28 20.3 21.5; 0.8
55–59 1.00 2.8 0.1; 5.6c 0.25 1.1 20.1; 2.3
60–64 1.00 0.8 21.9; 3.6 0.99 0.6 20.4; 1.7
65–69 1.00 1.7 22.2; 5.7 1.00 0.6 20.9; 2.2
Overall 0.65 2.5 1.3; 3.8c 0.29 0.3 20.2; 0.8
aP-value for the existence of a change point in trend obtained from the Poisson transition change-point model adjusted by screening region. Analyses performed for
each 5-year age group and for the overall.
bAnnual percentage change and 95% confidence intervals (95%CI) obtained from the Poisson regression model adjusted by screening region and participation status
(first or subsequent screen). Analyses performed for each 5-year age group and for the overall.
cSignificant trend at the 95% CI.
doi:10.1371/journal.pone.0083121.t003
Figure 1. Age-adjusted rates of screen detected breast cancer for first and subsequent screens, in the 1992–2006 period. Rates are
given per 100,000 women-years and are standardized using the European standard population in 5-year age groups as reference. The annual
percentage change (APC) and its 95% confidence intervals (95%CI) were estimated from the Poisson regression model adjusted by age and screening
region. A) Age-adjusted rates of invasive cancer for first and subsequent screens, and estimated APC and 95%CI. B) Age-adjusted rates of screen
detected ductal carcinoma in situ (DCIS) for first and subsequent screens, and estimated APC and 95%CI.
doi:10.1371/journal.pone.0083121.g001
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ranged from 3.9% in the 45–49 years age group to 2.8% in the
55–59 years age group, and was not statistically significant for the
60–64, and 65–69 years age groups. Previous studies have also
shown a highest proportion of DCIS among younger women [35].
The observed rates of screen detected DCIS and invasive cancer
appeared to be independent of HRT use among screened women.
An absence on change points in the overall trends was observed in
all the analyses performed: screen detected DCIS and invasive
breast cancer, first and subsequent screens, and 5-years age
groups. If HRT use has had an effect in the screen detected rates
of DCIS or invasive cancer we would expect to find a change point
in the overall trends. The change in trend would be strongly
expected after the year 2002 when the Women’s Health Initiative
trial was published [14], causing a reduction in the use of HRT
among post menopausal women [17]. Figure 2 shows a reduction
in the use of HRT starting in 2002, while the screen detected rates
of DCIS and invasive cancer remain steady over the study period.
Nevertheless, the time lag between the observed decreasing trend
in HRT use and its impact in breast cancer incidence may be long.
A reduction in screen detected breast cancer incidence may be
observed in a longer term outside the end of our study period in
2006. However, we studied a four year offset from the reduction in
the use of HRT in 2002 to the end of the study period in 2006.
Several developed countries have reported data on population
breast cancer incidence associated with a decrease in the use of
HRT in shorter study periods, ranging from 2 to 5 years of offset
[4–10]. On the other hand, longer duration of HRT use is known
to increase women’s breast cancer risk. However, an increased
breast cancer risk is consistent for all estrogen plus progestin HRT
users. The increased risk remains5-years or more after stop of
HRT use [36]. In our study women were considered to be HRT
users if they reported to be current users or to have used hormone
therapy in the sixth months previous to the screening examination.
The definition used ensures that HRT users had been users in a
recent period (,6 months) avoiding misclassification of past users
as current users.
We found that first and subsequent screens had similar trend
patterns for both, invasive cancers and DCIS. By presenting the
data for first and subsequent screens separately we avoided a
potential confounding factor when analyzing long-term data for
screen detected cancers. Higher screen detection rates were
observed at first screens compared to subsequent screens, which
was expected. However, the proportion of first and subsequent
screens changes over time, with more first screenings performed as
screening programmes are implemented during the study period,
and in younger women who are first time invited. Not taking into
consideration the participation when studying incidence trends in
mammography screening may cause empirical estimators to be
biased and confounded.
The widespread adaption of screening mammography once
screening saturation was nearly achieve has been used to justify the
observed downturn in the population incidence rates of invasive
breast cancer reported since the early 2000 in women on the 45–
69 age range [11,12]. During the 1990s screening programs were
implemented in the corresponding populations, and screening
mammography was widespread adapted. Most programs achieved
full coverage of the target populations during the late 1990s and
early 2000’s [12,26,37]. The steady, stable detection rate of
invasive cancers along the study period found in this study does
not support the downturn in the incidence rates of invasive breast
Figure 2. Rates of screen detected invasive cancer, screen detected ductal carcinoma in situ (DCIS), and hormone replacement
therapy (HRT) use among screened women, in the 1992–2006 period. Rates are given per 100,000 women-years and are standardized to the
age and first or subsequent screen using the European standard population in 5-year age groups as reference.
doi:10.1371/journal.pone.0083121.g002
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cancer observed in the population since the early 2000
[4,5,7,8,10]. On the other hand, our findings could help to
explain the increase in the population incidence of DCIS found in
several studies [18–22]. The proportion of women in the
population undergoing routine screening mammography will
influence population-based estimates of breast cancer incidence
[6]. The observed steady increase of DCIS in the proportion of
screen detected breast malignancies from 13% to 17% is expected
to influence the population incidence of DCIS. Previous studies
have reported that over 67% of Spanish women in the 45–69 age
range perform screening mammography in a publicly founded
screening programme [26].
If the natural progression of invasive breast cancer is via DCIS,
the detection of DCIS would help to prevent the development of
breast carcinomas and consequently reduce breast cancer mortal-
ity [38]. However, the increasing number of screen detected
DCIS, while the number of invasive cancers remains stable may
present a clinical challenge if it implies an increase in the number
of women overdiagnosed and overtreated [39].
Some limitations must be considered when interpreting our
findings. Firstly, we did not have individual level data on non-
participating women in the target population as we received
anonymized data of screened women only from the participating
regions. The attendance rate among invited women is reported to
be 67% [26], and the re-attendance rate among participating
women to be 91% [26]. The reported attendance and re-
attendance rates are not dissimilar to other well established
population-based screening programs in Europe [40]. It would
have been desirable to have information on breast cancer risk
factors among non-participating women. A previous study on
usage of screening mammography previous to initiating a
population-based breast cancer screening program in Spain
showed that utilization of mammography was higher among
younger women, women who had a higher education level, a
family history of breast cancer, personal history of benign breast
lesion, or had previous visits to a physician [41]. In addition, a
substantial proportion of women in the 45–69 age range undergo
opportunistic screening outside a screening programme [42].
Thus, the interpretations of the results in this study are related to
detection in population-based screening, and its implication in the
general population incidence should be carefully reviewed.
However, a not dissimilar trend in screen detected DCIS and
invasive cancer would be expected over time for population-based
and opportunistic screening, as the changes in the interpretation of
screening mammograms have occurred simultaneously. Besides,
6.6% of screen detected cancers in our study could not be classified
as DCIS or invasive breast cancer because the histology
classification was not available. The proportion of unknown
histology of screen detected cancers decreased over time, as the
screening programmes’ databases achieved completeness and the
established quality indicators were met. There were 9.5%
unknown histology cancers cases in 1992, 6.2% in 1999, and
3.3% in 2006. To check whether the reduction in unknown
histology cancer cases could have an effect in the observed increase
in screen detected DCIS we performed a sensitivity analysis
excluding the two screening regions with a highest proportion of
unknown histology cancer cases at the beginning of the study
period. No significant differences were observed compared to the
analysis including all regions, therefore all cases were included in
the analysis.
Conclusions
We studied the trends in screen detected DCIS and invasive
breast cancer over a 15 year period, and found that the studied
rates were independent of HRT use among screened women.
Despite the observed downturn in the population incidence of
invasive cancers, the screen detected rates of invasive cancers
remained steady, stable over the study period, while the screen
detected rates of DCIS steadily increased, causing an increase of
DCIS in the proportion of screen detected breast malignancies.
The increasing trend of screen detected DCIS was associated to
younger ages, particularly women aged 45–60 years. The study
provides substantial information to improve the knowledge about
the impact of screening programmes over time. These results are
particularly useful when the benefits and harms of screening
mammography are evaluated in the long-term.
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